2025 年核酸药物品牌推荐 技术迭代浪潮下的创新领航者 | 一、市场背景 | 2 | | --- | --- | | 1.1 摘要 | 2 | | 1.2 核酸药物定义 | 2 | | 1.3 市场演变 | 2 | | 二、市场现状 | 3 | | 2.1 市场规模 | 3 | | 2.2 市场供需 | 3 | | 三、市场竞争 | 4 | | 3.1 市场评估维度 | 4 | | 3.2 市场竞争格局 | 5 | | 3.3 十大品牌推荐 | 5 | | 四、发展趋势 | 7 | | 4.1 技术突破驱动：肝外递送与 AI 设计引领创新浪潮 | 7 | | 4.2 商业化加速：License-out 与医保支付共促市场扩容 | 7 | | 4.3 政策与资本双轮驱动：全链条支持构建产业生态 | 7 | | 4.4 适应症拓展：从罕见病向慢性病与肿瘤领域渗透 | 8 | 2025 年核酸药物品牌推荐 一、市场背景 1.1 摘要 2018 年，全球第一款 siRNA 药物 Patisiran 获批，推动了整个行业向广角度治疗领域扩 张。仅在 2018 至 2020 年间，就有 4 款 siRNA 药物和 3 ...

Group 1 - The core focus of the company is on the research and development of circular RNA drugs, positioning itself as a high-tech enterprise in the nucleic acid drug sector [1] - The company has established partnerships with leading global firms such as Agilent, Thermo Fisher, and Merck to drive innovation from drug development to industrialization [1] - Currently, the company has seven research pipelines, including ODC drugs for tumors and immune therapy antibody drugs, with some pipelines already entering preclinical research stages [1] Group 2 - The company plans to expand its research pipelines to ten by the end of the year and has initiated preparations for business development transactions [1]

Core Viewpoint - The innovation logic of the biopharmaceutical industry is undergoing adjustments due to intensified global competition, evolving technology platforms, and changing capital and regulatory environments. Systematic innovation capability and translational efficiency are becoming key factors influencing the industry's sustainable output [2]. Event Overview - The third Global Biopharmaceutical Conference 2026 will be held on April 16, 2026, at the Zhongguancun Conference Center, aiming to connect research, clinical, corporate, capital, and regulatory aspects of biopharmaceutical innovation [2][19]. - The conference will feature three main components: the release of a white paper, award evaluations, and multi-theme forums, presenting a comprehensive view of the global biopharmaceutical innovation ecosystem and development trends [2][9]. White Paper Release - The conference will officially release the "2026 Global Biopharmaceutical Innovation White Paper," focusing on technology evolution, product pipeline layout, corporate development paths, and changes in industry structure, providing valuable industry observation frameworks for enterprises, investors, and industry practitioners [9][10]. - The white paper serves as a significant window for companies to showcase their technological platform capabilities, research depth, and industry positioning [10]. Award Evaluation - The conference will announce multiple annual awards evaluating various dimensions of biopharmaceutical innovation, emphasizing long-term innovation capabilities rather than short-term market performance [11][12]. - Categories for awards include Annual Biopharmaceutical Innovation Enterprise, Annual Innovative Drug Product Award, Annual Technology Platform Innovation Award, and Annual Clinical Translation Innovation Award [15]. Multi-Theme Forums - The forums will address high-interest and collaborative potential topics in the biopharmaceutical industry, including trends in innovative drug development, antibody and ADC technologies, cell and gene therapy frontiers, nucleic acid drugs and delivery technologies, and biopharmaceutical innovation commercialization discussions [13][14]. - The forums aim to create a multi-perspective dialogue system involving various industry roles, enhancing collaboration and knowledge sharing [16]. Audience Composition - The conference targets a diverse audience, including research and clinical experts, biopharmaceutical company R&D and management teams, industry observers, investment institution representatives, and experts in registration, regulation, and payment [18][20]. - The event is positioned as an industry-focused, research-oriented, and systematic conference rather than a purely academic or promotional meeting [18].

Core Insights - The Fifth Guanghua Forum held at Fudan University focuses on the integration of cutting-edge technologies such as artificial intelligence and brain-machine interfaces with translational medicine, aiming to enhance innovation in drug development and therapies [1] Group 1: Forum Objectives and Themes - The forum aims to create a high-end platform for exchanging ideas and connecting resources, facilitating the integration of clinical medical applications, basic research, and industrial technological innovation in the life and health sector [1] - Key topics discussed include innovative drugs, translational medicine, smart medicine, and brain-machine interfaces, reflecting the rapid development and deep integration in the life health field [1] Group 2: Expert Insights and Future Directions - The Guanghua Life Health Association plans to focus on results transformation by organizing project showcases and facilitating direct communication to empower early-stage innovation projects from alumni [2] - Experts highlight that nucleic acid drugs represent a new wave in drug development, with significant recognition in the form of Nobel Prizes in 2023 and 2024, underscoring their importance in biomedical advancement [2] - Recommendations include establishing a regulatory science-based approval system to overcome challenges in the translation of synthetic biology technologies into the health industry, fostering a collaborative and competitive ecosystem [2] Group 3: Collaborative Initiatives - A cooperation intention agreement was signed between the Macau Translational Medicine Center and Fudan University Pudong Hospital to establish a research institute focused on micro-nano intelligent sensing medicine [3] - The research institute will prioritize clinical needs and focus on micro-nano sensing technology, microfluidics, and organ-on-chip research, aiming to develop platforms for drug screening and precision medicine diagnostics [3] - The institute will also leverage the strengths of the Macau Translational Medicine Center in traditional Chinese medicine technology and internationalization to create a cross-regional research and transformation hub [3]

（来源：上观新闻） 12月23日下午，"聚力赋能，共创未来——临港集团生物医药产业专场对接会暨2025年度临创蓝湾基金 LP大会"在漕河泾会议中心圆满举行。本次大会聚焦生物医药核心赛道，致力于搭建园区产业与资本机 构精准对接、共生共赢的高端生态平台，为上海建设具有全球影响力的生物医药产业创新高地助力赋 能。中国科学院院士马大为、葛均波，市科委生物技术和医药处处长、二级巡视员曹宏明，临港集团副 总裁龚伟、总审计师熊国利，生物医药相关行业协会、产业发展联盟，投资机构以及企业代表出席活 动。 为强化创新投资赋能，临创资本与临创蓝湾基金向精准医学研究与产业发展联盟副主席、上海医学创新 发展基金会执行理事长王波、上海临床创新转化研究院副总裁王立言、国泰海通证券医疗健康行业负责 人王莉、道彤投资创始管理合伙人孙琦等行业顶尖专家颁发聘书，为基金投资决策、项目培育孵化、投 后管理赋能提供全方位支持。 现场，"核酸药物临床转化概念验证中心"正式启幕，标志着临港在生物医药细分赛道的生态布局进一步 完善。该中心由上海临床创新转化研究院和临港园区企业泰楚生物共同发起成立，聚焦核酸类创新药物 从早期研发到临床应用的转化瓶颈，构建覆盖核 ...

Core Viewpoint - The integration of technology, talent, and policy tools in the Yangtze River Delta region is crucial for the development and cross-domain collaboration of the biopharmaceutical industry, which has already surpassed a scale of 1.2 trillion yuan, accounting for about one-third of the national total [1] Group 1: Industry Development and Collaboration - The biopharmaceutical industry in the Yangtze River Delta is expected to benefit from the expansion of the international innovation center, leading to better integration of scientific resources across cities [1][2] - The Shanghai Technology Exchange has established a biopharmaceutical special board to address challenges in technology assessment and investment cycles, facilitating 1,835 transactions with a total value exceeding 38 billion yuan [2] - The G60 Science and Technology Corridor in the Yangtze River Delta has 9 cities with 9,813 biopharmaceutical companies, representing 14.67% of the national total, indicating a strong cluster effect [3] Group 2: Regulatory and Policy Tools - Regulatory cooperation agreements among the drug monitoring departments of the three provinces and one city have been signed to enhance efficient development in the biopharmaceutical sector [4] - There is a need for improved tracking of the implementation of signed framework agreements to ensure effective cross-regional collaboration [5] Group 3: Capital Participation and Investment Trends - By 2025, the total investment in the biopharmaceutical sector in the Yangtze River Delta is projected to reach 150 billion yuan, accounting for 45% of the national total, with Shanghai and Jiangsu leading in financing [6] - Companies are increasingly seeking opportunities for pilot testing and production in surrounding areas due to lower labor costs and more available space [6][7] - The establishment of biopharmaceutical funds in the G60 Science and Technology Corridor aims to integrate resources from Shanghai and surrounding cities to support industry development [7] Group 4: Future Opportunities and Strategic Recommendations - The intelligent pharmaceutical sector driven by AI and big data is expected to see significant growth, with AI playing a role in target discovery and clinical design optimization [8] - Companies are advised to actively engage in regional collaborative ecosystems and leverage clinical resources to reduce transformation costs [8] - Emphasis should be placed on addressing unmet clinical needs and ensuring the domestic production of key materials to enhance cost competitiveness [8]

Core Insights - Jiangsu Province's Science and Technology Department has announced the first batch of major provincial science and technology projects for 2025, focusing on "Innovative Biopharmaceuticals" [1] - Suzhou leads the province with 11 selected projects, accounting for 58% of the total proposed projects, highlighting its strength and innovation in the biopharmaceutical sector [1] Project Distribution - The selected projects in Suzhou show a significant concentration, with 8 projects from Suzhou Industrial Park, and 1 each from Zhangjiagang, Suzhou High-tech Zone, and Suzhou University, indicating a cluster advantage in the biopharmaceutical industry [1] - Research directions include cancer treatment, neurological diseases, infection control, innovative drug delivery, and core industrial equipment, aiming to address clinical treatment challenges and industry development bottlenecks [1] Focus on Clinical Needs - Several projects target unmet clinical needs, focusing on cutting-edge therapies, such as the development of "safe and efficient personalized mRNA tumor vaccines" and "targeted KRAS mutation-enhanced TCR-T cell therapy drugs," providing new treatment solutions for malignant tumors, neurodegenerative diseases, and infectious diseases [1] Technological Advancements - Projects like "novel inhalation delivery system for nucleic acid drugs targeting major lung diseases" and "efficient and precise targeted nucleic acid delivery platform technology development" focus on enhancing the efficiency and industrialization of biopharmaceutical R&D across the entire drug development chain [2] - Significant progress has been made in key equipment and platform construction for biopharmaceutical R&D, with projects such as "AI-assisted design of new biopharmaceutical chromatography consumables and big data platform for separation and purification" and "high-parameter high-purity spectral flow cytometry analysis and sorting instruments" aimed at achieving self-controllable core R&D equipment and materials [2] Recognition and Future Potential - The outstanding performance of Suzhou in the provincial science and technology major projects reflects a high recognition of its current biopharmaceutical R&D capabilities and showcases its immense innovation potential in cutting-edge biopharmaceutical technologies [2] - The implementation and advancement of these projects are expected to significantly promote innovation breakthroughs and clinical transformation processes in biopharmaceutical technologies, continuously injecting new momentum into the treatment of major diseases and the development of the biopharmaceutical industry [2]

Core Insights - QYResearch has established a strong brand reputation due to frequent citations by renowned domestic and international companies, securities firms, and media outlets, ensuring the credibility and professionalism of its industry analyses and customized reports [1] Group 1: Market Predictions - The global sodium-ion battery market is projected to reach a sales figure of 152.13 billion yuan by 2031, with a compound annual growth rate (CAGR) of 88.9% [3] - The global medical device market is expected to reach 862.6 billion USD by 2030, driven by factors such as aging population, rising chronic disease prevalence, and advancements in medical technology [5][51] - The global eVTOL market is anticipated to grow from 14.8 billion USD in 2024 to 220 billion USD by 2031, with a CAGR of 45% [7] - The global automotive interior and exterior parts market is expected to reach 149 billion USD in 2024, 157.18 billion USD in 2025, and 224.23 billion USD by 2031, with a CAGR of 6% [9] - The global commercial cleaning robot market is projected to reach 1.71 billion USD by 2031, indicating significant growth potential [11] - The global MLCC release film market is estimated to grow from 3.678 billion USD in 2024 to 5.792 billion USD by 2031, with a CAGR of approximately 6.8% [21] - The global household NAS device market is expected to grow from 2.44 billion yuan in 2023 to 28.93 billion yuan by 2030 [25] Group 2: Company Performance - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. is leveraging the AI wave in healthcare to tap into a 6 trillion yuan international market [5] - Zhejiang Tiancheng Self-Control Co., Ltd. reported a 158% increase in net profit in Q3, driven by the low-altitude economy [7] - Huaxi Biological Technology Co., Ltd. reported nearly 1 billion yuan in revenue for Q3, with a net profit increase of over 50% [17] - Jiangsu Double Star Plastic New Materials Co., Ltd. is breaking through technology monopolies in the MLCC release film and carrier copper foil sectors [21] Group 3: Industry Trends - The global market for sodium-ion batteries is expected to see rapid growth, reflecting a shift towards alternative energy storage solutions [3] - The medical device sector is experiencing robust growth due to demographic changes and technological advancements [5][51] - The eVTOL market is gaining traction as urban air mobility solutions become more viable [7] - The automotive parts market is evolving with increasing demand for innovative interior and exterior solutions [9] - The commercial cleaning robot market is expanding as automation in cleaning processes becomes more prevalent [11]

Group 1 - The "China Medical Port" core area has attracted over 1,800 enterprises, with the life and health industry scale exceeding 50 billion [1] - The area has introduced 29 innovation platforms, including institutions like the Chinese Academy of Sciences and Zhejiang University [1] - In the past three years, 90 innovative drugs have entered clinical research stages, with 34 "unicorn" companies, the highest in the city [1] Group 2 - The Qiantang District has established the first nucleic acid drug industry cluster in the province, named "Hangzhou Nucleic Acid Drug Valley" [2] - The district has been included in provincial and municipal lists for cultivating future industry pilot zones in synthetic biology [2] - A talent matrix combining strategic scientists, leading entrepreneurs, and skilled craftsmen has been created, recognized as a pilot project for integrated education and technology talent reform in Zhejiang Province [2]

Core Viewpoint - Shenzhen Wego Biological Products Co., Ltd. successfully won the bidding for state-owned construction land use rights in Guangming District, Shenzhen, for a price of RMB 60.4 million, which aligns with the company's strategic development plan for establishing an intelligent industrial base [1] Group 1: Land Acquisition Details - The company participated in the bidding for the land use rights of plot A628-0045, covering an area of 69,986.43 square meters, with a usage period of 30 years [1] - The funding for this land acquisition will come from the company's own or self-raised funds, and it does not constitute a related party transaction or a major asset restructuring as per regulations [1] Group 2: Strategic Implications - The acquisition of the land is intended to support the company's intelligent industrial base project, which is crucial for the company's high-quality development [1] - Upon completion of the new industrial base, the company plans to relocate its operations and will cooperate with the Guangming District government to facilitate the recovery of the existing factory site [1]